Bristol-Myers Squibb Company (BMY)
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?
BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular portfolio faces mixed developments.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
Bristol-Myers Squibb: Dividend/Portfolio Renewal Thesis Remains Promising
Bristol-Myers Squibb's new Opdivo Qvantig injectable delivery is expected to secure additional 20Y patent protection, with their efforts to drive physician adoption before 2028 likely to temper top-line erosion risks. Their portfolio renewal is progressing well, with the Growth Portfolio already comprising 59.2% of its FQ4'25 revenues (+7.2 points YoY/+55.9 from FY2021 levels of 3.3%). BMY's robust cash flows and manageable net debt levels support their secure dividend investment thesis, even amid increased R&D and M&A activities.
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.
Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty
Bristol-Myers Squibb remains a "Buy," offering a high dividend and free cash flow yield amid recent market pullback. BMY's Growth Portfolio drove 16% YoY net sales growth, offsetting Legacy Portfolio declines; 2026 revenue guidance is $46–$47.5 billion with EPS of $6.05–$6.35. Technical support is seen in the mid-$50s, with fair value near $70 and long-term breakout potential to $85 if resistance at $63 is breached.
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug declines.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top Stock Picks of 2026: Bristol-Myers Squibb
For the final few weeks of the first quarter we're going to highlight one of Schaeffer's top 15 picks for 2026.
These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity
A death cross forms when a stock's 50-day moving average crosses below its 200-day moving average, signaling a potential downtrend.
20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style
After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
